Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mastermind-like transcriptional coactivator 3 (MAML3) is a nuclear protein that acts as a versatile transcriptional coactivator. It is a member of the mastermind-like family, functioning primarily in the nucleus to integrate Notch signaling with other pathways, including the WNT/β-catenin and IGF1R/AKT cascades, thereby modulating cell fate, differentiation, and proliferation. MAML3’s canonical role involves binding to intracellular Notch domains and promoting transcription by RNA polymerase II; however, recurrent MAML3 gene fusions (e.g., UBTF–MAML3) have been found in aggressive cancers such as pheochromocytomas, paragangliomas, sarcomas, and others, where they drive aberrant gene expression programs that contribute to tumorigenicity, invasion, and therapy resistance. Aberrant expression or gene fusion of MAML3 is associated with poor prognosis and increased metastatic potential in several cancer types. In non-cancer contexts, MAML3 has associations with other biological processes including angiogenesis and bronchial hyperresponsiveness in asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mastermind-like transcriptional coactivator 3 (MAML3).